The obesity duopoly has been pierced as Amgen positions itself to have a drug on the market in a few years. While this adds ...

Few companies garner as much reliable attention as Novo Nordisk (NYSE: NVO) does these days. With a bull market coinciding ...

Novo Nordisk faces challenges in weight-loss sector, but acquisition and strong diabetes portfolio position it for future ...

In the subsequent 5 years to follow, Novo Nordisk’s newest products, presently in FDA trials, are targeting the obesity market. It is anticipated to reach $100 billion by 2030. Obesity drugs ...

The plans from the Department of Health and Human Services come on the heels of criticism Ozempic and other weight loss ...

Medicare and Medicaid would cover weight-loss drugs like Wegovy and Ozempic under a new rule proposed by President Joe Biden ...

Semaglutide being investigated for applications in heart disease, Alzheimer's, liver disease, and moreGLP-1 drugs expected to generate multi-hundreds of billions of revenues in the years to come ...

The good news is that HHS recognizes that vitally important anti-obesity medicines like Wegovy and Zepbound should be made available to all Americans, regardless of income. The bad news is that unless ...

Euroinvestor.dk reports that coffee prices have hit their highest point since 1972, as the cost of arabica beans continues to rise. A futures contract for one pound of coffee (about 0.45 kg) now costs ...

Semaglutide being investigated for applications in heart disease, Alzheimer's, liver disease, and moreGLP-1 drugs expected to generate multi-hundreds of billions of revenues in the years to come KELOW ...